A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

Trial Details

NCT ID
NCT06616766
Phase
PHASE1 / PHASE2
Sponsor
Yuhan Corporation
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • YH42946
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Seongnam-si, Gyeonggi-do, South Korea|37.43861,127.13778
  • Suwon, Gyeonggi-do, South Korea|37.29111,127.00889
  • Cheongju-si, North Chungcheong, South Korea|36.63722,127.48972
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • ECOG performance status 0 or 1
  • Estimated life expectancy of at least 3 months
  • Patients who have progressed on or after all available standard therapies or for whom standard treatment is inappropriate
  • Mandatory provision of archived or fresh tumor tissue in quantity sufficient to allow for retrospective confirmation of HER2 aberration or EGFR mut…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →